Otomax hc
The Virginia Premier Health Plan pharmacy benefit is administered by Express Scripts. Unless exceptions are noted, generally all applicable dosage forms and strengths of the drug cited are on the preferred drug list. Preferred Drug List is a combination of open and closed therapeutic classes. The Virginia Premier Preferred Drug List Preface: The Committee utilizes this opportunity to ensure adherence to previously established formulary placement recommendations, and to recommend any additional changes to ensure that the formulary is clinically appropriate. The drug evaluation documents include, at a minimum: Summary of the pharmacology Safety Efficacy Dosage Mode of administration Relative place in therapy of the medication Approved indications Adverse effects Comparison Studies Medical outcome and pharmacoeconomic studies On an annual basis, the National P&T Committee will review the final formulary recommendations, by drug class, for the upcoming plan year. The drug evaluation documents are developed with the aid of a wide range of resources including, but not limited to: primary literature, clinical practice guidelines, and FDA-approved package inserts. Express Scripts' clinical team conducts a search of the medical literature, evaluates published data from clinical trials, and develops comprehensive drug evaluation summary documents. The Express Scripts P&T Committee will consider all non-specialty FDA approved drugs for inclusion on the Preferred Drug List. To provide pharmaceutical products and clinical services in keeping with the highest quality of patient care by incorporating the principles of Quality Management in the most cost effective manner. Please send your comments to: Medical Director Virginia Premier Health Plan, Inc. All responses will be reviewed and considered.
Your input is vital to this Clinical Preferred Drug List's continued success. Your comments and suggestions regarding this Clinical Preferred Drug List are encouraged. The goal of the preferred drug list is to provide clinically efficacious, safe, and cost-effective pharmacological therapies based on prospective, concurrent and retrospective peer reviewed medical literature. The decisions of the P&T Committee will be communicated in the Virginia Premier Provider Relations Newsletter, Epocrates and individual provider mailings as necessary. The P&T Committee meets regularly to evaluate drugs and develop policy concerning the preferred drug list and drug utilization management. The Express Scripts National P&T Committee consists of non-employee physician members and pharmacist from active community and academic-based practices and represents a broad range of medical specialties. Decisions for non-specialty drugs selected for the closed classes are made by the Express Scripts Pharmacy & Therapeutics (P&T) Committee. Drugs or medications not on our Preferred Drug List can be reviewed through the Prior Authorization process. This Preferred Drug List includes Closed Classes whereby only the drugs listed with the classes are covered. Pharmacy and Therapeutics (P&T) Committee Actions: Closed Class List This allows us to advise patients to keep unfinished drops for potential future use with beneficial economic implications.Read V7H_VPHP_Preferred%20Drug%20List.pdf text version It is likely these findings apply to other antimicrobial drops and for other organisms. aeruginosa over at least 4 months from opening, or that the bottle contents become contaminated after use in patients with culture-positive otorrhea. There appears to be no evidence that antimicrobial ear drops containing either gentamicin or ciprofloxacin lose their efficacy against either S. The drop solution itself also showed no contamination after having been opened for 4 months and used by a patient. Of drops returned after use on infected patients, none of the cultures from the teats of the bottle grew any organisms. Neither antibiotic showed deterioration in effectiveness against either microorganism over a 4-month period, as assessed by the size of inhibitory zones on inoculated agar plates. In addition, drops used for 1 week on patients with culture-positive otorrhea were analyzed for contamination of both the bottle teat and the drop solution. Bottles were also assessed for contamination once opened. Their effectiveness was assessed on agar plates inoculated with both Staphylococcus aureus and Pseudomonas aeruginosa. We aimed to determine appropriate recommendations for the shelf life of common antibiotic-containing topical otic solutions.Įar drops containing gentamicin and ciprofloxacin were analyzed. The advice given to patients regarding the shelf life of antimicrobial ear drops is based on little or no evidence.